West Pharmaceutical Services (WST) Projected to Post Quarterly Earnings on Thursday

West Pharmaceutical Services (NYSE:WST) is projected to release its earnings data before the market opens on Thursday, February 13th. Analysts expect West Pharmaceutical Services to post earnings of $1.71 per share and revenue of $740.87 million for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

West Pharmaceutical Services Price Performance

WST opened at $335.54 on Thursday. The company has a current ratio of 3.00, a quick ratio of 2.23 and a debt-to-equity ratio of 0.07. The business’s fifty day simple moving average is $332.25 and its 200-day simple moving average is $314.42. The company has a market capitalization of $24.30 billion, a price-to-earnings ratio of 49.78, a PEG ratio of 19.82 and a beta of 1.01. West Pharmaceutical Services has a 12-month low of $265.00 and a 12-month high of $413.70.

West Pharmaceutical Services Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 11th. Shareholders of record on Friday, February 7th will be issued a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a yield of 0.25%. The ex-dividend date of this dividend is Friday, February 7th. West Pharmaceutical Services’s payout ratio is 12.46%.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on WST. Bank of America upped their price target on shares of West Pharmaceutical Services from $350.00 to $355.00 and gave the stock a “buy” rating in a research report on Friday, December 13th. Citigroup began coverage on West Pharmaceutical Services in a report on Wednesday, January 8th. They set a “buy” rating and a $400.00 target price for the company. UBS Group upgraded West Pharmaceutical Services from a “neutral” rating to a “buy” rating and lifted their price target for the company from $350.00 to $390.00 in a report on Thursday, December 12th. Wolfe Research started coverage on West Pharmaceutical Services in a research note on Friday, December 13th. They set a “peer perform” rating for the company. Finally, StockNews.com upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research note on Friday, January 31st. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $430.20.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.